Sei Investments CO Nektar Therapeutics Transaction History

Sei Investments CO

$74.7 Billion
Q3 2024

A detailed history of Sei Investments CO transactions in Nektar Therapeutics stock. As of the latest transaction made, Sei Investments CO holds 62,498 shares of NKTR stock, worth $58,123. This represents 0.0% of its overall portfolio holdings.

Number of Shares

62,498

Holding current value

$58,123

% of portfolio

0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$1.11 - $1.48 $69,372 - $92,497	62,498 New	62,498 $81,000
Q4 2023 Feb 14, 2024	SELL	$0.42 - $0.57 $4 - $5	-10 Reduced 0.04%	23,000 $12,000
Q2 2023 Aug 11, 2023	SELL	$0.53 - $1.03 $2,352 - $4,571	-4,438 Reduced 16.17%	23,010 $13,000
Q1 2023 May 12, 2023	BUY	$0.64 - $3.15 $2,840 - $13,979	4,438 Added 19.29%	27,448 $19,000
Q4 2022 Feb 10, 2023	BUY	$2.03 - $4.28 $10,149 - $21,400	5,000 Added 27.76%	23,010 $52,000
Q4 2021 Feb 14, 2022	SELL	$10.83 - $18.41 $444 - $754	-41 Reduced 0.23%	18,010 $243,000
Q3 2021 Nov 12, 2021	SELL	$13.07 - $18.84 $79,818 - $115,055	-6,107 Reduced 25.28%	18,051 $323,000
Q2 2021 Aug 06, 2021	SELL	$16.52 - $20.4 $49 - $61	-3 Reduced 0.01%	24,158 $410,000
Q1 2021 May 12, 2021	SELL	$16.56 - $25.46 $19,722 - $30,322	-1,191 Reduced 4.7%	24,161 $477,000
Q4 2020 Feb 08, 2021	BUY	$15.77 - $19.03 $3,832 - $4,624	243 Added 0.97%	25,352 $427,000
Q3 2020 Dec 04, 2020	SELL	$16.59 - $24.79 $282 - $421	-17 Reduced 0.07%	25,109 $415,000
Q3 2020 Nov 06, 2020	BUY	$16.59 - $24.79 $71,967 - $107,539	4,338 Added 20.87%	25,126 $415,000
Q2 2020 Aug 17, 2020	BUY	$16.86 - $23.44 $62,736 - $87,220	3,721 Added 21.8%	20,788 $480,000
Q2 2020 Aug 11, 2020	SELL	$16.86 - $23.44 $28,442 - $39,543	-1,687 Reduced 9.0%	17,067 $367,000
Q1 2020 May 14, 2020	BUY	$14.47 - $27.96 $23,918 - $46,217	1,653 Added 9.67%	18,754 $332,000
Q4 2019 Feb 06, 2020	BUY	$15.87 - $23.12 $271,392 - $395,375	17,101 New	17,101 $368,000
Q3 2019 Nov 12, 2019	SELL	$16.91 - $36.27 $121,718 - $261,071	-7,198 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$31.0 - $36.3 $19,623 - $22,977	633 Added 9.64%	7,198 $259,000
Q1 2019 May 15, 2019	SELL	$31.58 - $46.35 $1.56 Million - $2.29 Million	-49,449 Reduced 88.28%	6,565 $224,000
Q4 2018 Feb 13, 2019	BUY	$30.43 - $56.65 $657,014 - $1.22 Million	21,591 Added 62.72%	56,014 $2.81 Million
Q3 2018 Nov 08, 2018	SELL	$46.46 - $68.49 $1.35 Million - $1.99 Million	-29,012 Reduced 45.74%	34,423 $2.1 Million
Q2 2018 Aug 03, 2018	SELL	$46.25 - $104.45 $1.56 Million - $3.53 Million	-33,795 Reduced 34.76%	63,435 $3.1 Million
Q1 2018 May 11, 2018	SELL	$57.4 - $108.44 $1.33 Million - $2.52 Million	-23,232 Reduced 19.29%	97,230 $10.3 Million
Q4 2017 Feb 08, 2018	SELL	$23.02 - $60.5 $2.71 Million - $7.13 Million	-117,868 Reduced 49.46%	120,462 $7.19 Million
Q3 2017 Nov 06, 2017	BUY	$17.79 - $24.0 $4.24 Million - $5.72 Million	238,330	238,330 $5.72 Million

Others Institutions Holding NKTR

# of Institutions

145

Shares Held

139M

Call Options Held

32.6K

Put Options Held

14.1K

Deep Track Capital, LP Greenwich, CT

15.9M
Shares

$14.8 Million
0.76% of portfolio
Black Rock Inc. New York, NY

15.2M
Shares

$14.1 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

13.1M
Shares

$12.2 Million
0.0% of portfolio
Eventide Asset Management, LLC Boston, MA

9.4M
Shares

$8.74 Million
0.22% of portfolio
Samlyn Capital, LLC New York, NY

9.2M
Shares

$8.56 Million
0.19% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

News

Stay updated on Sei Investments CO with notifications on news.

Account